Drugmakers Boost U.S. Investments Amid Tariff Concerns
Global pharmaceutical companies are ramping up investments in U.S. manufacturing amid potential tariffs on imports. Major firms like GSK, Roche, and AstraZeneca are planning significant financial commitments to bolster domestic production, mitigate supply-chain risks, and reassure investors, with investments collectively topping hundreds of billions over the coming years.
Pharmaceutical giants are intensifying their focus on U.S. manufacturing as the Trump administration considers imposing steep tariffs on drug imports. This shift is a strategic maneuver to safeguard their supply chains and maintain investor confidence.
Several companies have unveiled substantial investments: GSK plans a $30 billion expenditure on U.S. infrastructure, while Roche announced a $550 million expansion in Indianapolis. Similarly, Eli Lilly, Johnson & Johnson, and AstraZeneca have each committed multi-billion-dollar investments towards augmenting their American operations.
These proactive measures, part of global firms' strategies, underscore a concerted effort to weather the impending tariff challenges by boosting domestic production capabilities significantly.
(With inputs from agencies.)
Google News